A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)

OBJECTIVE: To evaluate the efficacy and safety of AVP-825, a drug–device combination of low-dose sumatriptan powder (22 mg loaded dose) delivered intranasally through a targeted Breath Powered device vs an identical device containing lactose powder (placebo device) in the treatment of migraine heada...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Headache
Main Authors: Cady, Roger K, McAllister, Peter J, Spierings, Egilius LH, Messina, John, Carothers, Jennifer, Djupesland, Per G, Mahmoud, Ramy A
Formato: Artigo
Idioma:Inglês
Publicado em: BlackWell Publishing Ltd 2015
Assuntos:
Research Submissions
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4320758/
https://ncbi.nlm.nih.gov/pubmed/25355310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.12472
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados